Work

J02 A global development program testing RG6042, an anti-sense oligonucleotide, for the treatment of early manifest huntington’s disease (hd)

Year: 2018

Type: conference-abstract

Source: Journal of Neurology Neurosurgery & Psychiatry

DOI: 10.1136/jnnp-2018-ehdn.262

Authors: Scott Schobel, Giuseppe Palermo, Dylan Trundell, Thomas Kremer, Patricia Sanwald-Ducray, Anne Smith, Lauren Boak, Rachelle Doody

Institutions: F. Hoffmann-La Roche AG, Roche (United Kingdom), Ionis Pharmaceuticals (United States), Genentech

Language: English

Topic: Genetic Neurodegenerative Diseases

Subfield: Cellular and Molecular Neuroscience

Field: Neuroscience

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2906009666

Cites:

Cited by: 3

Related to: 10